Old dogs and new tricks – drug repurposing for rare diseases
In the same week as rare disease day and a summit on CAR-TCR looking at the ‘value’ assessment for incredible new gene and cell therapies...
Contributors
-
Joint Head of Behavioural Science -
Account Manager -
-
Associate Consultant -
Joint Head of Behavioural Science -
President, USA -
Vice President, Business Development -
Senior Consultant -
-
Publications Executive -
Project Director -
-
Strategic Communications Director -
Associate Consultant -
Executive Chairman -
Consultant -
-
-
Senior Consultant -
Consultant -
Senior Consultant -
SVP -
Master Practitioner: Patient Insights -
Publications Assistant -
EVP, Oncology Practice Head -
EVP, Patient Solutions -
-
US CEO -
-
Associate Editorial Director
-
Sr. Research Analyst -
-
Principal -
Research Executive -
Account Director -
-
-
Head of MedErgy (CH-MedErgy) -
-
Managing Consultant -
Project Manager -
Project Director -
Executive Vice President, Strategic Collaborations -
Associate Consultant
Cello Health Archive
- April 2021 (2)
- March 2021 (4)
- January 2021 (1)
- December 2020 (1)
- November 2020 (1)
- October 2020 (2)
- September 2020 (3)
- August 2020 (6)
- July 2020 (3)
- June 2020 (1)
- May 2020 (1)
- April 2020 (2)
- March 2020 (6)
- February 2020 (19)
- January 2020 (4)
- December 2019 (3)
- November 2019 (4)
- October 2019 (1)
- September 2019 (2)
- August 2019 (4)
- July 2019 (4)
- June 2019 (4)
- May 2019 (12)
- April 2019 (11)
- March 2019 (5)
- February 2019 (12)
- January 2019 (1)
- October 2018 (2)
- August 2018 (5)
- July 2018 (7)
- June 2018 (5)
- May 2018 (5)
- April 2018 (6)
- March 2018 (9)
- February 2018 (11)
- January 2018 (4)
- December 2017 (8)
- November 2017 (21)
- October 2017 (35)
- September 2017 (18)
- August 2017 (1)
- July 2017 (1)
- June 2017 (1)
- May 2017 (2)
- April 2017 (2)
- March 2017 (1)
- February 2017 (2)
- January 2017 (1)
- December 2016 (1)
- October 2016 (1)
Rare Diseases, cell therapies and the value conundrum - food for thought
Considerations around ‘value’ assessment for gene and cell therapies in rare diseases was a theme addressed by several speakers, to close...
Kite (a Gilead company) release unpublished data demonstrating the key determinants influencing durable responses in large B cell lymphoma patients treated with YESCARTA CAR-T therapy
Dr. Adrian Bot (VP of Translational Medicine – Kite, a Gilead Company) provides an update on the factors determining durable responses...
A look into the future - gene /cell therapy provision at the ‘coal face’
As a passionate advocate for gene and cell therapies, Fiona Thistlethwaite (Medical Oncology Consultant at The Christie Hospital &...
Multi-Tumour-Associated Antigen-Specific (MultiTAA) T Cells offer a promising therapeutic approach vs. CAR-T to effectively combat an array of cancers
Really insightful talk delivered by Dr. Mythill Koneru (Chief Medical Officer – Marker Therapeutics) @ the CAR-TCR Summit Europe 2020
Accelerating cell therapies into the clinic - what’s your philosophy?
A thoughtful overview from Dr Richard Zajicek (Medicine and Process Delivery Leader, GSK) at the CAR-TCR Europe Summit2020, outlining the...
CAR-T therapy - just as much a process as a product!
Great talk by Dr. Dalip Sethi (Senior Scientist - Terumo BCT) @ the opening of the CAR-TCR Europe 2020 conference highlighting the many...
Patient intelligence and artificial intelligence combine to bring rare disease breakthroughs
As Rare Disease day approaches, it seems timely to reflect on some of what's new in rare disease.
A new scientific paper published...
Innovation in a Buyer’s Market: Standing out in an Increasingly Crowded and Diversified Cancer Treatment Algorithm (a Cancer Progress contribution)
Imagine being told that you are about to be dropped into a deep and deadly hole with nothing but a grappling hook to pull yourself out....
Oncology 2020, the Coming Decade’s Visionary Advances - Part III
In pondering the ongoing discoveries and nascent technologies that could advance the treatment of cancer in the coming decade, I am not...
Hit the Road Running, an Introduction to Publications
As part of the 2020 European meeting of ISMPP, I attended the Training zone ‘#HITTHEPUBROADRUNNING’, presented by Caroline Halford...
Seen any good films lately? Try the Rare film festival!
Rare Disease UK hosted the UK’s first ever film festival fully dedicated to raising awareness of rare diseases. Charities, rare disease...
Oncology 2020, the Coming Decade’s Visionary Advances—Part II
Pondering those cancer circuitry maps such as the one from the updated classic "Hallmarks of Cancer: The Next Generation" by Hanahan and...
The ubiquitous target question for anticancer modalities
Continuing on this theme that Joel has raised in his recent post (“CD19 and BCMA – ‘What if This is as Good as it Gets?’”), I would like...
CD19 and BCMA – “What if This is as Good as it Gets?”
I’m no fortune-teller. But I can predict with a reasonable amount of certainty that, in the next week or so, we’ll see a press...
Packing a Punch with Beautiful Data
I was fortunate enough to spend a day with some of our team, and fellow publications professionals at the 2020 European ISMPP conference.
Bringing real-world commercial experience and consulting expertise to help navigate complexity in an evolving Life Sciences sector
Ahead of the 6th annual LSX World Congress, Steve Mather, CEO of Cello Health Consulting reflects on supporting an evolving Life Science...
ISMPP EU 2020: Enhancing value across the data journey
It’s noisy and crowded out there – never has it been so challenging to find novel and cost-effective ways to create an impact with...
Oncology 2020, the Coming Decade’s Visionary Advances—Part I
As we enter this new decade, it behooves us to both appreciate and laud advances that have been made in Oncology over the past thirty...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net